Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherCellular and Molecular

Chlorogenic acid inhibits epithelial-mesenchymal transition and invasion of breast cancer by down-regulating LRP6

Wei Xue, Jie Hao, Qiuping Zhang, Ronghua Jin, Zhuo Luo, Xin Yang, Yanying Liu, Qinpei Lu, Yiqiang Ouyang and Hongwei Guo
Journal of Pharmacology and Experimental Therapeutics December 1, 2022, JPET-AR-2022-001189; DOI: https://doi.org/10.1124/jpet.122.001189
Wei Xue
1Guangxi Key Laboratory for Research and Evaluation of Bioactive Molecules& College of Pharmacy, Guangxi Medical University, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wei Xue
Jie Hao
2Guangxi Medical University, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hongweiguo@gxmu.edu.cn
Qiuping Zhang
2Guangxi Medical University, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hongweiguo@gxmu.edu.cn
Ronghua Jin
1Guangxi Key Laboratory for Research and Evaluation of Bioactive Molecules& College of Pharmacy, Guangxi Medical University, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhuo Luo
1Guangxi Key Laboratory for Research and Evaluation of Bioactive Molecules& College of Pharmacy, Guangxi Medical University, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xin Yang
3Key Laboratory of Longevity and Aging-related Diseases of Chinese Ministry of Education & Center for Translational Medicine, Guangxi Medical University, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yanying Liu
1Guangxi Key Laboratory for Research and Evaluation of Bioactive Molecules& College of Pharmacy, Guangxi Medical University, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qinpei Lu
1Guangxi Key Laboratory for Research and Evaluation of Bioactive Molecules& College of Pharmacy, Guangxi Medical University, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yiqiang Ouyang
4Laboratory Animal Center, Guangxi Medical University, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongwei Guo
5Guangxi Key Laboratory for Research and Evaluation of Bioactive Molecules& College of Pharmacy, Key Laboratory of Longevity and Aging-related Diseases of Chinese Ministry of Education & Center for T, Guangxi Medical University, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hongweiguo@gxmu.edu.cn
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Epithelial-mesenchymal transition (EMT) plays a crucial role in breast cancer metastasis and inhibition of EMT may be an effective approach to suppress metastatic breast cancer. High LRP6 expression is usually observed in breast cancer and predicts poor prognosis. In present study, we investigated whether chlorogenic acid (CA) has an EMT inhibitory effect on breast cell lines and underlying molecular mechanism. We found that CA treatment transformed MCF-7 cell morphology from spindle shape (mesenchymal phenotype) to spherical shape (epithelial phenotype). CA clearly increased epithelial markers' expression (E-cadherin and ZO-1) but decreased mesenchymal markers' expression (ZEB1, N-cadherin, Vimentin, Snail and Slug). In addition, CA attenuated MMP-2 and MMP-9 activities and inhibited cell migration and invasion. CA also down-regulated LRP6 expression, knockdown LRP6 with siRNA repressed cell mobility and invasion while overexpression of LRP6 promoted EMT and antagonized the EMT inhibitory effect of CA on MCF-7 cells. In vivo study showed that CA significantly reduced tumor volume and tumor weight. Immunohistochemical analysis demonstrated that CA inhibited xenograft tumor EMT with LRP6 and Vimentin decreased and E-cadherin increased. In conclusion, CA restrained EMT and invasion of breast cancer through down-regulating LRP6 expression. CA may be developed as an EMT inhibitor for breast cancer treatment.

Significance Statement chlorogenic acid (CA), one of the most common polyphenol compounds in traditional Chinese medicine, repressed EMT and weakens cellular mobility and invasion in MCF-7 cells. The mechanism studies demonstrated that CA inhibits MCF-7 cell EMT and invasion via targeting LRP6. Additionally, CA could inhibit tumor growth and xenograft tumor EMT in vivo. The EMT inhibitory property of CA warrants further studies of CA as a drug candidate for the treatment of metastatic breast cancer.

  • breast cancer
  • Metastasis
  • © 2020 The Authors. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited and is not used for commercial purposes.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 384 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 384, Issue 2
1 Feb 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Chlorogenic acid inhibits epithelial-mesenchymal transition and invasion of breast cancer by down-regulating LRP6
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherCellular and Molecular

Chlorogenic acid inhibits breast cancer metastasis

Wei Xue, Jie Hao, Qiuping Zhang, Ronghua Jin, Zhuo Luo, Xin Yang, Yanying Liu, Qinpei Lu, Yiqiang Ouyang and Hongwei Guo
Journal of Pharmacology and Experimental Therapeutics December 1, 2022, JPET-AR-2022-001189; DOI: https://doi.org/10.1124/jpet.122.001189

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherCellular and Molecular

Chlorogenic acid inhibits breast cancer metastasis

Wei Xue, Jie Hao, Qiuping Zhang, Ronghua Jin, Zhuo Luo, Xin Yang, Yanying Liu, Qinpei Lu, Yiqiang Ouyang and Hongwei Guo
Journal of Pharmacology and Experimental Therapeutics December 1, 2022, JPET-AR-2022-001189; DOI: https://doi.org/10.1124/jpet.122.001189
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • SNAP25 and mGluRs Control Pathological Tau Release
  • N-Stearoylethanolamine Inhibits Platelet Reactivity
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics